Pharmaceutical Executive, November 2022 Issue (PDF)

Publication
Article
Pharmaceutical ExecutivePharmaceutical Executive-11-01-2022
Volume 42
Issue 11

Click cover to access PDF

Download Issue PDF
Articles in this issue
Labs and Computing Power: The Missing Link for a Revolution by 2030
Labs and Computing Power: The Missing Link for a Revolution by 2030
A Culture of Quality: The Catalyst to Accelerate Innovation
A Culture of Quality: The Catalyst to Accelerate Innovation
Whole-Person Care: Are We Ready? The Intersection of Pharma and Digital Therapeutics
Whole-Person Care: Are We Ready? The Intersection of Pharma and Digital Therapeutics
A Mission of the Heart
A Mission of the Heart
The New Reality for Industry Dealmaking May be Setting In
The New Reality for Industry Dealmaking May be Setting In
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?
Digital Biomarkers Could Reshape CNS Diagnosis, Treatment
Digital Biomarkers Could Reshape CNS Diagnosis, Treatment
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?
Recaps, Live & In Person
Recaps, Live & In Person
Pharmaceutical Executive, November 2022 Issue (PDF)
Pharmaceutical Executive, November 2022 Issue (PDF)
FDA Keeps Its User Fees, but Fails to Gain Important Reforms
FDA Keeps Its User Fees, but Fails to Gain Important Reforms
Recent Videos
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content
March Pharmaceutical Industry Movers & Shakers

March Pharmaceutical Industry Movers & Shakers

Miranda Schmalfuhs
March 31st 2025
Article

A monthly roundup of business and people news in the pharmaceutical industry.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Don Tracy, Associate Editor
March 31st 2025
Article

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

Jennifer Butler

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
March 11th 2025
Podcast

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate

Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate

Don Tracy, Associate Editor
March 28th 2025
Article

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders.

Credit: WrightStudio | stock.adobe.com

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success

Shana Gunderson Hua, PharmD; Nancy Pham, PharmD; and Pete Vaccaro
March 28th 2025
Article

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.